CALCULATIONS - ML OZ (FL) 5 ML = 1 TSP 250ML = 1 CUP
1 teaspoon (tsp) = 5 mL 1 tablespoon (Tbsp) = 15 mL
1 Tbsp = 3 tsp 1 mL ≈ 20 drops
1 g = 1,000 mg 1 mg = 1,000 mcg 10% THC ≈ 100 mg/g
20% THC ≈ 200 mg/g mg/mL = tincture/oil concentration
CALCULATIONS - ML OZ (FL) 5 ML = 1 TSP 250ML = 1 CUP
1 teaspoon (tsp) = 5 mL 1 tablespoon (Tbsp) = 15 mL
1 Tbsp = 3 tsp 1 mL ≈ 20 drops
1 g = 1,000 mg 1 mg = 1,000 mcg 10% THC ≈ 100 mg/g
20% THC ≈ 200 mg/g mg/mL = tincture/oil concentration
IMPORTANT CALCULATIONS
1 g = 1,000 mg 1 mg = 1,000 mcg
10% THC ≈ 100 mg THC/g 20% THC ≈ 200 mg THC/g
1 mL = 20 drops approximately
mg/mL = concentration for oils/tinctures
THC:CBD ratio: 1:1 balanced; 1:10 CBD-dominant
2.5–5 mg THC = common low oral dose
Cannabinoids added below, with the full mood-support framework reformatted as an outline. Cannabinoid mood evidence is strongest for CBD in anxiety (low-to-moderate certainty) and for cannabinoids in sleep, whereas depression shows trivial-to-no benefit and THC-predominant products carry substantial psychiatric risk. [1-3]
Only CBD (Epidiolex) is FDA-approved, and only for seizures—not any mood indication. [4]
I. Anxiety / stress
A. Cannabinoids
CBD (cannabidiol): Acute 300–600 mg reduces anxiety in simulated public speaking; daily 150–300 mg over 4–15 weeks may reduce symptoms in GAD/social anxiety disorder (low certainty). Meta-analysis: oral CBD large effect on anxiety symptoms (Hedges g = −0.92). Inverted U-shaped dose response—benefit may diminish at higher doses. [1-2][5]
THC: Biphasic/dose-dependent—low dose (7.5 mg) may reduce anxiety, higher dose (12.5 mg) induces anxiety. CBD may attenuate THC-induced anxiety. [1][6]
Cannabigerol (CBG): Preliminary interest as an acute anxiolytic; unverified. [1]
Overall RCT signal: Cannabinoids reduced anxiety symptoms (SMD −0.40), but evidence is indirect/low-certainty. [3]
B. Terpenes: Linalool, limonene, α-pinene (GABAergic/glutamatergic, preclinical); β-caryophyllene and citral (human inhalation RCT lowered STAI anxiety). [7-9]
C. Aromatherapy: Lavender (best human data), bergamot. [7-8][10]
D. Meditation: Mindfulness lowers cortisol, CRP, heart rate, systolic BP; improves emotional regulation. [11]
II. Low mood / depression
A. Cannabinoids: RCTs show trivial-to-no antidepressant effect (SMD −0.20, NS); no benefit demonstrated. Observational UK registry data suggest PHQ-9 improvement but high risk of bias, no causal inference. THC worsened anxiety/psychotic symptoms in >50% of hospitalized depressed patients in older trials. Co-morbid cannabis use in MDD is associated with increased suicidal ideation and attempts. [3][12-14]
B. Terpenes: β-caryophyllene (CB2-mediated, preclinical). [7]
C. Aromatherapy: Ylang-ylang, neroli, sweet orange, rose, geranium, frankincense (HPA-axis calming). [7]
D. Meditation (strongest overall evidence): MBCT cuts relapse ~31%; mindfulness reduces active depressive symptoms (SMD −1.14); MBCT/ACT/DBT effective transdiagnostically. [15-17]
III. Insomnia / sleep-related mood disturbance
A. Cannabinoids: Meta-analysis of 10 RCTs (n=2134)—reduced insomnia severity (MD −3.73) and improved sleep quality (MD −3.94); non-CBD (THC-containing) formulations more effective than CBD-only. Adverse events (dizziness, dry mouth) more frequent. Note: World Sleep Society and Kaiser Permanente guidelines recommend against use, citing insufficient evidence. [2][18-19]
B. Terpenes: Myrcene, limonene, linalool (sedative, zebrafish/inhalation data). [7][15]
C. Aromatherapy: Lavender (reduces sleep latency). [15]
IV. Low arousal / poor concentration / ADHD
A. Cannabinoids: Not recommended—the single ADHD RCT (THC:CBD spray) showed no significant cognitive or symptom benefit; acute intoxication mimics ADHD deficits. [1][20-21]
B. Terpenes/aromatherapy: 1,8-cineole (eucalyptol), rosemary, clary sage (dopaminergic, cognitive-enhancing). [7][22]
V. Premenstrual mood symptoms
Aromatherapy: Lavender (RCT reduced PMS anxiety, depressed affect, nervousness). [7]
Cannabinoid safety — critical qualifiers
Concern
Detail
References
Psychosis risk
High-potency THC in adolescents/young adults: ~2- to 11-fold increased psychosis risk
[1, 23]
Bipolar disorder
THC worsens mania symptoms and function; avoid
[1]
Suicidality
Increased suicidal ideation/self-harm in mood disorders, dose-dependent
[1, 14]
Cannabis use disorder
~3 in 10 past-year users; ~29% of medicinal users
[1-2]
Society positions
APA, ASAM recommend against cannabis for any psychiatric disorder; VA/DoD strongly against for PTSD
[2, 14]
Avoid entirely
Adolescents, pregnancy, bipolar/psychotic disorders, SUD risk
[1, 23]
The following table details the potential adverse effects clinicians should counsel on before any cannabinoid trial for mood:
Table 4. Potential Adverse Effects of Cannabis Use
Therapeutic Use of Cannabis and Cannabinoids. JAMA. November 26, 2025.
Content used under license from the JAMA Network®
© American Medical Association
Practical framing: Among cannabinoids, purified CBD has the most favorable risk-benefit for anxiety and is the only agent with an FDA-approved (non-mood) formulation, while THC-predominant products carry the greatest psychiatric risk and no proven mood benefit.
[1][23]
None of these—terpenes, aromatherapy, cannabinoids, or meditation—should replace guideline-based pharmacotherapy/psychotherapy for moderate-to-severe mood disorders; meditation-based interventions (MBCT/mindfulness) retain the strongest human evidence base of any modality listed here.
[3][15]
1.
Cannabis and Mental Health: A Review.
JAMA Internal Medicine. 2026. Kansagara D, Terry GE, Ayers CK, D'Souza DC.RecentReview
2.
Therapeutic Use of Cannabis and Cannabinoids: A Review.
The Journal of the American Medical Association. 2026. Hsu M, Shah A, Jordan A, Gold MS, Hill KP.RecentReview
3.
Psychiatry Research. 2026. Bharat C, Huang X, Campbell G, et al.RecentSR
4.
FDA Orange Book. 2026.
5.
Neuroscience and Biobehavioral Reviews. 2022. Narayan AJ, Downey LA, Manning B, Hayley AC.SR
6.
Measuring the Effects of Cannabis on Anxiety and Depression Among Cancer Patients.
Cancer Medicine. 2025. Reddy AC, Hampton JM, Park SJ, et al.Recent
7.
Effects of essential oils on central nervous system: Focus on mental health.
Phytotherapy Research : PTR. 2021. Lizarraga-Valderrama LR.Review
8.
Phytotherapy Research : PTR. 2017. Han X, Gibson J, Eggett DL, Parker TL.
9.
Scientific Reports. 2022. Johnson A, Stewart A, El-Hakim I, Hamilton TJ.
10.
Current Pharmaceutical Design. 2025. Sivamaruthi BS, Chaiyasut C, Suganthy N, et al.Review
11.
Current Psychiatry Reports. 2024. Kucukosmanoglu HS, Cramer H, Tavakoly R, Moosburner A, Bilc MI.Review
12.
Psychiatric Services. 2021. Stanciu CN, Brunette MF, Teja N, Budney AJ.SR
13.
UK Medical Cannabis Registry: A Two-Year Case Series of Clinical Outcomes in Depression.
Journal of Affective Disorders. 2026. Lillywhite E, Erridge S, Clarke E, et al.Recent
14.
Resource Document on Opposition to Cannabis as Medicine.
American Psychiatric Association (2018). 2018. Guideline
15.
Efficacy of Mindfulness-Based Cognitive Therapy in Prevention of Depressive Relapse.
JAMA Psychiatry. 2016. Kuyken W, Warren FC, Taylor RS, et al.SR
16.
Scientific Reports. 2024. Fu Y, Song Y, Li Y, et al.SR
17.
Psychiatry Research. 2025. Alkan E, Kumar G, Ravichandran S, et al.SR
18.
Sleep Medicine. 2026. Asim R, Azeem B, Wijdan SA, et al.RecentReview
19.
Sleep Medicine Reviews. 2025. da Silva GHS, Barbosa EC, de Lima FR, et al.RecentReview
20.
Cannabis Use in Attention - Deficit/Hyperactivity Disorder (ADHD): A Scoping Review.
Journal of Psychiatric Research. 2023. Francisco AP, Lethbridge G, Patterson B, Goldman Bergmann C, Van Ameringen M.Review
21.
European Child & Adolescent Psychiatry. 2024. Rice LJ, Cannon L, Dadlani N, et al.SR
22.
Anxiolytic Terpenoids and Aromatherapy for Anxiety and Depression.
Advances in Experimental Medicine and Biology. 2020. Agatonovic-Kustrin S, Kustrin E, Gegechkori V, Morton DW.Review
23.
BMJ. 2023. Solmi M, De Toffol M, Kim JY, et al.SR
Cannabinoids added below, with the full mood-support framework reformatted as an outline. Cannabinoid mood evidence is strongest for CBD in anxiety (low-to-moderate certainty) and for cannabinoids in sleep, whereas depression shows trivial-to-no benefit and THC-predominant products carry substantial psychiatric risk. [1-3]
Only CBD (Epidiolex) is FDA-approved, and only for seizures—not any mood indication. [4]
I. Anxiety / stress
A. Cannabinoids
CBD (cannabidiol): Acute 300–600 mg reduces anxiety in simulated public speaking; daily 150–300 mg over 4–15 weeks may reduce symptoms in GAD/social anxiety disorder (low certainty). Meta-analysis: oral CBD large effect on anxiety symptoms (Hedges g = −0.92). Inverted U-shaped dose response—benefit may diminish at higher doses. [1-2][5]
THC: Biphasic/dose-dependent—low dose (7.5 mg) may reduce anxiety, higher dose (12.5 mg) induces anxiety. CBD may attenuate THC-induced anxiety. [1][6]
Cannabigerol (CBG): Preliminary interest as an acute anxiolytic; unverified. [1]
Overall RCT signal: Cannabinoids reduced anxiety symptoms (SMD −0.40), but evidence is indirect/low-certainty. [3]
B. Terpenes: Linalool, limonene, α-pinene (GABAergic/glutamatergic, preclinical); β-caryophyllene and citral (human inhalation RCT lowered STAI anxiety). [7-9]
C. Aromatherapy: Lavender (best human data), bergamot. [7-8][10]
D. Meditation: Mindfulness lowers cortisol, CRP, heart rate, systolic BP; improves emotional regulation. [11]
II. Low mood / depression
A. Cannabinoids: RCTs show trivial-to-no antidepressant effect (SMD −0.20, NS); no benefit demonstrated. Observational UK registry data suggest PHQ-9 improvement but high risk of bias, no causal inference. THC worsened anxiety/psychotic symptoms in >50% of hospitalized depressed patients in older trials. Co-morbid cannabis use in MDD is associated with increased suicidal ideation and attempts. [3][12-14]
B. Terpenes: β-caryophyllene (CB2-mediated, preclinical). [7]
C. Aromatherapy: Ylang-ylang, neroli, sweet orange, rose, geranium, frankincense (HPA-axis calming). [7]
D. Meditation (strongest overall evidence): MBCT cuts relapse ~31%; mindfulness reduces active depressive symptoms (SMD −1.14); MBCT/ACT/DBT effective transdiagnostically. [15-17]
III. Insomnia / sleep-related mood disturbance
A. Cannabinoids: Meta-analysis of 10 RCTs (n=2134)—reduced insomnia severity (MD −3.73) and improved sleep quality (MD −3.94); non-CBD (THC-containing) formulations more effective than CBD-only. Adverse events (dizziness, dry mouth) more frequent. Note: World Sleep Society and Kaiser Permanente guidelines recommend against use, citing insufficient evidence. [2][18-19]
B. Terpenes: Myrcene, limonene, linalool (sedative, zebrafish/inhalation data). [7][15]
C. Aromatherapy: Lavender (reduces sleep latency). [15]
IV. Low arousal / poor concentration / ADHD
A. Cannabinoids: Not recommended—the single ADHD RCT (THC:CBD spray) showed no significant cognitive or symptom benefit; acute intoxication mimics ADHD deficits. [1][20-21]
B. Terpenes/aromatherapy: 1,8-cineole (eucalyptol), rosemary, clary sage (dopaminergic, cognitive-enhancing). [7][22]
V. Premenstrual mood symptoms
Aromatherapy: Lavender (RCT reduced PMS anxiety, depressed affect, nervousness). [7]
Cannabinoid safety — critical qualifiers
Concern
Detail
References
Psychosis risk
High-potency THC in adolescents/young adults: ~2- to 11-fold increased psychosis risk
[1, 23]
Bipolar disorder
THC worsens mania symptoms and function; avoid
[1]
Suicidality
Increased suicidal ideation/self-harm in mood disorders, dose-dependent
[1, 14]
Cannabis use disorder
~3 in 10 past-year users; ~29% of medicinal users
[1-2]
Society positions
APA, ASAM recommend against cannabis for any psychiatric disorder; VA/DoD strongly against for PTSD
[2, 14]
Avoid entirely
Adolescents, pregnancy, bipolar/psychotic disorders, SUD risk
[1, 23]
The following table details the potential adverse effects clinicians should counsel on before any cannabinoid trial for mood:
Table 4. Potential Adverse Effects of Cannabis Use
Therapeutic Use of Cannabis and Cannabinoids. JAMA. November 26, 2025.
Content used under license from the JAMA Network®
© American Medical Association
Practical framing: Among cannabinoids, purified CBD has the most favorable risk-benefit for anxiety and is the only agent with an FDA-approved (non-mood) formulation, while THC-predominant products carry the greatest psychiatric risk and no proven mood benefit.
[1][23]
None of these—terpenes, aromatherapy, cannabinoids, or meditation—should replace guideline-based pharmacotherapy/psychotherapy for moderate-to-severe mood disorders; meditation-based interventions (MBCT/mindfulness) retain the strongest human evidence base of any modality listed here.
[3][15]
1.
Cannabis and Mental Health: A Review.
JAMA Internal Medicine. 2026. Kansagara D, Terry GE, Ayers CK, D'Souza DC.RecentReview
2.
Therapeutic Use of Cannabis and Cannabinoids: A Review.
The Journal of the American Medical Association. 2026. Hsu M, Shah A, Jordan A, Gold MS, Hill KP.RecentReview
3.
Psychiatry Research. 2026. Bharat C, Huang X, Campbell G, et al.RecentSR
4.
FDA Orange Book. 2026.
5.
Neuroscience and Biobehavioral Reviews. 2022. Narayan AJ, Downey LA, Manning B, Hayley AC.SR
6.
Measuring the Effects of Cannabis on Anxiety and Depression Among Cancer Patients.
Cancer Medicine. 2025. Reddy AC, Hampton JM, Park SJ, et al.Recent
7.
Effects of essential oils on central nervous system: Focus on mental health.
Phytotherapy Research : PTR. 2021. Lizarraga-Valderrama LR.Review
8.
Phytotherapy Research : PTR. 2017. Han X, Gibson J, Eggett DL, Parker TL.
9.
Scientific Reports. 2022. Johnson A, Stewart A, El-Hakim I, Hamilton TJ.
10.
Current Pharmaceutical Design. 2025. Sivamaruthi BS, Chaiyasut C, Suganthy N, et al.Review
11.
Current Psychiatry Reports. 2024. Kucukosmanoglu HS, Cramer H, Tavakoly R, Moosburner A, Bilc MI.Review
12.
Psychiatric Services. 2021. Stanciu CN, Brunette MF, Teja N, Budney AJ.SR
13.
UK Medical Cannabis Registry: A Two-Year Case Series of Clinical Outcomes in Depression.
Journal of Affective Disorders. 2026. Lillywhite E, Erridge S, Clarke E, et al.Recent
14.
Resource Document on Opposition to Cannabis as Medicine.
American Psychiatric Association (2018). 2018. Guideline
15.
Efficacy of Mindfulness-Based Cognitive Therapy in Prevention of Depressive Relapse.
JAMA Psychiatry. 2016. Kuyken W, Warren FC, Taylor RS, et al.SR
16.
Scientific Reports. 2024. Fu Y, Song Y, Li Y, et al.SR
17.
Psychiatry Research. 2025. Alkan E, Kumar G, Ravichandran S, et al.SR
18.
Sleep Medicine. 2026. Asim R, Azeem B, Wijdan SA, et al.RecentReview
19.
Sleep Medicine Reviews. 2025. da Silva GHS, Barbosa EC, de Lima FR, et al.RecentReview
20.
Cannabis Use in Attention - Deficit/Hyperactivity Disorder (ADHD): A Scoping Review.
Journal of Psychiatric Research. 2023. Francisco AP, Lethbridge G, Patterson B, Goldman Bergmann C, Van Ameringen M.Review
21.
European Child & Adolescent Psychiatry. 2024. Rice LJ, Cannon L, Dadlani N, et al.SR
22.
Anxiolytic Terpenoids and Aromatherapy for Anxiety and Depression.
Advances in Experimental Medicine and Biology. 2020. Agatonovic-Kustrin S, Kustrin E, Gegechkori V, Morton DW.Review
23.
BMJ. 2023. Solmi M, De Toffol M, Kim JY, et al.SR
Balanced CBD:THC, approximately 1:1, with a β caryophyllene rich terpene profile, has the best available support as a starting point.
Human evidence remains low to very low certainty, particularly for specific terpene combinations. Cannabis products are generally considered later line therapy after standard neuropathic pain medications have failed or are not tolerated.
Ratio
Evidence / Considerations
Balanced, ~1:1
Best human evidence. May provide modest improvement in neuropathic pain with better tolerability than THC dominant products.
THC dominant
May modestly reduce pain, but increases dizziness, sedation, nausea, and cognitive effects.
CBD dominant
Lower psychoactive risk, but substantially weaker evidence for analgesia.
CBD alone
Generally well tolerated, but has not demonstrated consistent benefit for chronic neuropathic pain.
Practical approach: Start with a balanced or CBD leaning product, use the lowest THC dose, and titrate slowly according to benefit and adverse effects.
β Caryophyllene: Strongest preclinical candidate for combined inflammatory and neuropathic pain. Acts primarily through CB2 receptors.
α Humulene: Anti inflammatory and analgesic activity, possibly involving TRPV1 modulation.
α Terpineol: Demonstrated reduction of mechanical allodynia and thermal hyperalgesia in animal models.
Linalool: Preclinical antinociceptive and neuropathic pain activity.
Limonene: Anti inflammatory and antinociceptive activity through several proposed pathways.
α Bisabolol: Potential neuropathic and inflammatory analgesia through calcium channel modulation.
Consider:
CBD:THC approximately 1:1
with emphasis on:
β caryophyllene + α humulene + linalool or α terpineol
Optional secondary terpenes include limonene or α bisabolol.
Terpene specific pain benefits and the proposed cannabis “entourage effect” remain largely preclinical and are not established by high quality human trials. THC related adverse effects remain dose dependent.